Boston Scientific Corporation (BSX)
| Market Cap | 66.06B -57.1% |
| Revenue (ttm) | 21.00B +13.5% |
| Net Income | 3.67B +46.7% |
| EPS | 2.47 +46.9% |
| Shares Out | 1.45B |
| PE Ratio | 18.47 |
| Forward PE | 14.23 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,931,214 |
| Open | 45.31 |
| Previous Close | 45.69 |
| Day's Range | 45.13 - 46.07 |
| 52-Week Range | 41.39 - 105.65 |
| Beta | 0.58 |
| Analysts | Buy |
| Price Target | 57.82 (+26.85%) |
| Earnings Date | Oct 28, 2026 |
About BSX
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatogra... [Read more]
Financial Performance
In 2025, Boston Scientific's revenue was $20.07 billion, an increase of 19.87% compared to the previous year's $16.75 billion. Earnings were $2.90 billion, an increase of 56.40%.
Financial StatementsAnalyst Summary
According to 30 analysts, the average rating for BSX stock is "Buy." The 12-month stock price target is $57.82, which is an increase of 26.85% from the latest price.
News
Boston Scientific to participate in Stifel's 2026 Healthcare Conference
MARLBOROUGH, Mass., Oct. 26, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Stifel's 2026 Healthcare Conference on Wednesday, November 11, 2026.
Boston Scientific price target lowered to $55 from $60 at Stifel
Stifel lowered the firm’s price target on Boston Scientific (BSX) to $55 from $60 and keeps a Buy rating on the shares.
3 Healthcare Stocks with Strong Buy Ratings and Double-Digit Upside
BioMarin Pharmaceutical ($BMRN), Boston Scientific ($BSX), and Ionis Pharmaceuticals ($IONS) are three healthcare stocks with Strong Buy ratings and double-digit upside, according to TipRanks. Leading...
Boston Scientific price target lowered to $51 from $57 at Truist
Truist lowered the firm’s price target on Boston Scientific (BSX) to $51 from $57 and keeps a Buy rating on the shares as part of a broader research note previewing…
Boston Scientific price target lowered to $55 from $60 at Mizuho
Mizuho lowered the firm’s price target on Boston Scientific (BSX) to $55 from $60 and keeps an Outperform rating on the shares. The firm adjusted targets in the medical devices…
Boston Scientific appoints Joseph Fitzgerald COO
Boston Scientific (BSX) announced the appointment of Joseph Fitzgerald to executive vice president and COO, effective Jan. 1, 2027. In this role, Fitzgerald will oversee the company’s global operation...
Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer
New operating structure designed to increase efficiency and support continued growth MARLBOROUGH, Mass., Oct. 7, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the appo...
Boston Scientific initiated with an Equal Weight at Barclays
Barclays initiated coverage of Boston Scientific (BSX) with an Equal Weight rating and $48 price target The firm rolled out coverage of the medical suppliers and devices group with a…
3 Large-Cap Stocks Down More Than 25% this Year That Analysts Still Love
Boston Scientific ($BSX), Tyler Technologies ($TYL), and AppLovin ($APP) are three large-cap stocks down more than 25% year-to-date. Yet all three stocks remain favored by analysts, with Strong Buy ra...
Citi cuts Boston Scientific target, opens ‘downside 90-day catalyst watch’
Citi lowered the firm’s price target on Boston Scientific (BSX) to $48 from $50 and keeps a Neutral rating on the shares. Citi also opened a “downside 90-day catalyst watch”…
Boston Scientific price target lowered to $54 from $60 at Bernstein
Bernstein analyst Lee Hambright lowered the firm’s price target on Boston Scientific (BSX) to $54 from $60 and keeps an Outperform rating on the shares. The firm cites reduced growth…
Elutia receives $8M payment from Boston Scientific
Elutia (ELUT) has received the full $8M held in escrow in connection with the sale of its BioEnvelope business to Boston Scientific (BSX). The payment was made following an indemnity…
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
Boston Scientific released the full $8 million holdback on schedule and with no claims Escrow release is the third funding catalyst Elutia has delivered in 2026, following the August closings of its A...
Boston Scientific price target lowered to $48 from $50 at Wells Fargo
Wells Fargo lowered the firm’s price target on Boston Scientific (BSX) to $48 from $50 and keeps an Equal Weight rating on the shares. The firm is lowering its Q3…
Boston Scientific price target lowered to $48 from $50 at Wells Fargo
Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Boston Scientific (BSX) to $48 from $50 and keeps an Equal Weight rating on the shares. Published first on…
Boston Scientific price target lowered to $65 from $85 at Oppenheimer
Oppenheimer analyst Suraj Kalia lowered the firm’s price target on Boston Scientific (BSX) to $65 from $85 and keeps an Outperform rating on the shares ahead of quarterly results. The…
Citi downgrades Boston Scientific to Neutral on uncertain recovery
Citi downgraded Boston Scientific (BSX) to Neutral from Buy with a price target of $50, down from $57. The company faces a “more mature” U.S. pulsed field ablation market with…
Boston Scientific downgraded to Neutral from Buy at Citi
Citi downgraded Boston Scientific (BSX) to Neutral from Buy with a $50 price target
Boston Scientific Restores Key Operations After Cyberattack
The company said products are moving through its distribution network at or above normal levels as the Marlborough, Mass., company works to fulfill customer orders, reduce backlogs and accelerate the ...
Boston Scientific Transcript: Wells Fargo 21st Annual Healthcare Conference
Operations have fully recovered from a global cyber attack, but financial guidance for Q3 and the full year will not be met. WATCHMAN faces market headwinds and new competition, while EP growth moderates amid strong product launches planned for 2027. The Penumbra acquisition and new platforms in cardiovascular and urology are expected to drive future growth.
Boston Scientific ‘Unlikely to Meet' Earnings Guidance After Cyberattack. Stock Falls.
Boston Scientific stock falls as the medical device maker says a recent cyberattack may make it hard to hit quarterly and full-year guidance targets.
Boston Scientific Won't Meet Guidance Due to Cyberattack
Boston Scientific said it likely won't meet its financial guidance due to the cyberattack that has disrupted its operations, sending shares of the medical-technology company down sharply in premarket ...
Boston Scientific says cyberattack likely to hurt 2026 sales, profit
Boston Scientific said on Tuesday a cybersecurity incident that disrupted manufacturing and order shipments globally is likely to have a material impact on its third-quarter and full-year 2026 ...
Boston Scientific Stock Slides After Cyberattack Caused ‘Global Disruption'
Boston Scientific's stock is sliding in the wake of a major cyberattack, adding to its recent woes.
Boston Scientific Stock Price Drops After Cyberattack Triggers Global Outage
The medical-device maker said order processing and shipping have been disrupted.